drug_type
RELEVANT_DRUG
intervention_type
Antibody-Drug Conjugate
drug_description
An intravenous antibody–drug conjugate (ABBV-400) consisting of a humanized anti–c-Met monoclonal antibody linked via a cleavable linker to a topoisomerase I–inhibitor payload; targets MET on tumor cells, is internalized, and releases the topo-I inhibitor to induce DNA damage and cell death with potential bystander effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti–c-Met monoclonal antibody linked via a cleavable linker to a topoisomerase I inhibitor. After binding MET on tumor cells, the ADC is internalized and the linker is cleaved to release the topo‑I inhibitor, causing DNA damage and cell death, with potential bystander killing of adjacent tumor cells.
drug_name
Telisotuzumab adizutecan
nct_id_drug_ref
NCT06464692